Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04755894 | HDDO-1756 Bio Equivalence Study | PHASE1 | COMPLETED | 56 | — | — | Jun 12, 2020 | Jul 27, 2020 | Feb 17, 2021 | 1 | South Korea |
Cmax
| Arm | Type | Description |
|---|---|---|
| group A | EXPERIMENTAL | - |
| group B | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| HDDO-1756 | DRUG | single dose |
| HDDO-17561/HDDO-17562 | DRUG | single dose |
Inclusion Criteria: 1. Healthy adult volunteers aged 19 or older during screening 2. A person who weighs more than 50.0 kg and has a BMI of 18.0 kg/m2 or less and 30.0 kg/m2 or less. ☞ BMI (kg/m2) = Weight (kg) / {Long (m)}2 3. A person who has no chronic disease or medical treatment and has no...